» Authors » Adam Platt

Adam Platt

Explore the profile of Adam Platt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 2438
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Gopalakrishnan V, Sparklin B, Kim J, Bouquet J, Kehl M, Kenny T, et al.
Respir Res . 2025 Jan; 26(1):45. PMID: 39885466
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by airway obstruction and inflammation. Non-typeable Haemophilus influenzae (NTHi) lung infections are common in COPD, promoting frequent exacerbations and...
2.
Scott I, Van Zuydam N, Cann J, Negri V, Tsafou K, Killick H, et al.
Mucosal Immunol . 2024 Dec; PMID: 39662674
Interleukin (IL)-33 is released following tissue damage, causing airway inflammation and remodelling via reduced IL-33 (IL-33)/serum stimulation-2 (ST2) and oxidised IL-33 (IL-33)/receptor for advanced glycation end products (RAGE)/epidermal growth factor...
3.
Burren O, Dhindsa R, Deevi S, Wen S, Nag A, Mitchell J, et al.
Nat Genet . 2024 Aug; 56(9):1832-1840. PMID: 39192095
Telomeres protect chromosome ends from damage and their length is linked with human disease and aging. We developed a joint telomere length metric, combining quantitative PCR and whole-genome sequencing measurements...
4.
Vanderstichele T, Burnham K, de Klein N, Tardaguila M, Howell B, Walter K, et al.
Am J Hum Genet . 2024 Jul; 111(8):1524-1543. PMID: 39053458
Gene misexpression is the aberrant transcription of a gene in a context where it is usually inactive. Despite its known pathological consequences in specific rare diseases, we have a limited...
5.
Baker T, Sharifian H, Newcombe P, Gavin P, Lazarus M, Ramaswamy M, et al.
Ann Rheum Dis . 2024 Apr; 83(8):1018-1027. PMID: 38569851
Introduction: Anifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated the immunomodulatory mechanisms of anifrolumab...
6.
Thillai M, Oldham J, Ruggiero A, Kanavati F, McLellan T, Saini G, et al.
Am J Respir Crit Care Med . 2024 Mar; 210(4):465-472. PMID: 38452227
Despite evidence demonstrating a prognostic role for computed tomography (CT) scans in idiopathic pulmonary fibrosis (IPF), image-based biomarkers are not routinely used in clinical practice or trials. To develop automated...
7.
van Laar J, Lei A, Safy-Khan M, Almquist J, Belfield G, Edman K, et al.
Clin Transl Sci . 2023 Oct; 16(12):2494-2506. PMID: 37873558
Oral corticosteroid use is limited by side effects, some caused by off-target actions on the mineralocorticoid receptor that disrupt electrolyte balance. AZD9567 is a selective, nonsteroidal glucocorticoid receptor modulator. The...
8.
Dhindsa R, Burren O, Sun B, Prins B, Matelska D, Wheeler E, et al.
Nature . 2023 Oct; 622(7982):339-347. PMID: 37794183
Integrating human genomics and proteomics can help elucidate disease mechanisms, identify clinical biomarkers and discover drug targets. Because previous proteogenomic studies have focused on common variation via genome-wide association studies,...
9.
Hristova V, Watson A, Chaerkady R, Glover M, Ackland J, Angerman B, et al.
ERJ Open Res . 2023 May; 9(3). PMID: 37228288
Rationale: Pulmonary surfactant is vital for lung homeostasis as it reduces surface tension to prevent alveolar collapse and provides essential immune-regulatory and antipathogenic functions. Previous studies demonstrated dysregulation of some...
10.
Kurki M, Karjalainen J, Palta P, Sipila T, Kristiansson K, Donner K, et al.
Nature . 2023 Feb; 615(7952):E19. PMID: 36829046
No abstract available.